b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="Publisher" Owner="NLM">\n        <PMID Version="1">32072742</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>04</Month>\n            <Day>22</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1463-1326</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>Feb</Month>\n                        <Day>19</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Diabetes, obesity &amp; metabolism</Title>\n                <ISOAbbreviation>Diabetes Obes Metab</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L Randomized Clinical Trial.</ArticleTitle>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1111/dom.14005</ELocationID>\n            <Abstract>\n                <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To assess efficacy and safety of fixed-ratio (1:1) combination insulin glargine and lixisenatide (iGlarLixi) compared to insulin glargine U100 (iGlar), with metformin, in Japanese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on basal insulin and oral antidiabetic drugs (OADs).</AbstractText>\n                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">This 26-week, randomized, open-label study compared iGlarLixi to iGlar, both with metformin in adult Japanese patients with T2DM and hemoglobin (Hb) A1c \xe2\x89\xa57.5% to \xe2\x89\xa49.5%, treated with basal insulin and 1 or 2 OADs. 512 patients were randomized after a 12-week run-in, when iGlar was introduced and/or further titrated and OADs other than metformin were stopped. The primary endpoint was change in HbA1c from baseline to week 26.</AbstractText>\n                <AbstractText Label="RESULTS" NlmCategory="RESULTS">iGlarLixi (n=255) demonstrated significantly greater reductions in HbA1c (-1.27%) than iGlar (n=257, -0.53%) (LS mean difference: -0.74%, P &lt;0.0001) at week 26, confirming the superiority of iGlarLixi. Significantly more iGlarLixi patients reached target HbA1c &lt;7% at week 26 (51.8% vs. 16.0% for iGlar). iGlarLixi patients lost weight in contrast to iGlar patients (-0.51kg vs. +0.55kg). Documented symptomatic hypoglycemia (plasma glucose \xe2\x89\xa43.9mmol/L) was observed in 18.8% of iGlarLixi patients vs. 16.7% of iGlar patients. iGlarLixi patients had more gastrointestinal-related adverse events than iGlar patients (33.3% vs. 8.6%), primarily nausea (16.9% vs. 0.8%). However, the treatment was generally well-tolerated.</AbstractText>\n                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A once-daily injection of iGlarLixi with metformin is an effective, well-tolerated, and simple therapeutic intervention providing significant improvement in glycemic control in Japanese patients with T2DM inadequately controlled on basal insulin and up to two OADs. Clinical Trial Number: NCT02752412 This article is protected by copyright. All rights reserved.</AbstractText>\n                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Kaneto</LastName>\n                    <ForeName>Hideaki</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Takami</LastName>\n                    <ForeName>Akane</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Research &amp; Development, Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Spranger</LastName>\n                    <ForeName>Robert</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Diabetes, Cardiovascular and Metabolics Development, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Amano</LastName>\n                    <ForeName>Atsushi</ForeName>\n                    <Initials>A</Initials>\n                    <Identifier Source="ORCID">https://orcid.org/0000-0003-3698-6871</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Research &amp; Development, Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Watanabe</LastName>\n                    <ForeName>Daisuke</ForeName>\n                    <Initials>D</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Research &amp; Development, Tokyo, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Niemoeller</LastName>\n                    <ForeName>Elisabeth</ForeName>\n                    <Initials>E</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Diabetes, Cardiovascular and Metabolics Development, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2020</Year>\n                <Month>02</Month>\n                <Day>19</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Diabetes Obes Metab</MedlineTA>\n            <NlmUniqueID>100883645</NlmUniqueID>\n            <ISSNLinking>1462-8902</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">GLP-1 analogue</Keyword>\n            <Keyword MajorTopicYN="N">basal insulin</Keyword>\n            <Keyword MajorTopicYN="N">glycemic control</Keyword>\n            <Keyword MajorTopicYN="N">metformin</Keyword>\n            <Keyword MajorTopicYN="N">phase 3 study</Keyword>\n            <Keyword MajorTopicYN="N">type 2 diabetes</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>12</Month>\n                <Day>13</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2020</Year>\n                <Month>02</Month>\n                <Day>06</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2020</Year>\n                <Month>02</Month>\n                <Day>14</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2020</Year>\n                <Month>2</Month>\n                <Day>20</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>2</Month>\n                <Day>20</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2020</Year>\n                <Month>2</Month>\n                <Day>20</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>aheadofprint</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">32072742</ArticleId>\n            <ArticleId IdType="doi">10.1111/dom.14005</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'